Diabetes Patents (Class 514/6.9)
-
Publication number: 20120114706Abstract: Methods and compositions for treating cancer and other disorders by ?-endorphin therapy are disclosed.Type: ApplicationFiled: November 9, 2011Publication date: May 10, 2012Inventor: Dipak Kumar Sarkar
-
Publication number: 20120108505Abstract: The present invention relates to compounds of the general formula (I): wherein R1, R2, R3, R5, s, and Z are selected independently of each other and are as defined herein, to compositions comprising the compounds, and methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.Type: ApplicationFiled: June 10, 2010Publication date: May 3, 2012Inventors: Eric J. Gilbert, Michael W. Miller, Andrew W. Stamford, William J. Greenlee
-
Publication number: 20120108507Abstract: The present disclosure provides a new technology platform that converts one type of cells (substrate cells) to another type of cells (product cells).Type: ApplicationFiled: November 3, 2011Publication date: May 3, 2012Applicant: VIVOSCRIPT, INC.Inventors: Yong Zhu, Shili Wu, Jun Bao
-
Publication number: 20120093815Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.Type: ApplicationFiled: December 16, 2011Publication date: April 19, 2012Applicant: Amgen Inc.Inventors: EDWARD JOHN BELOUSKI, MURIELLE MARIE ELLISON, AGNES EVA HAMBURGER, RANDY IRA HECHT, YUE-SHENG LI, MARK LEO MICHAELS, JEONGHOON SUN, JING XU
-
Publication number: 20120094904Abstract: The invention provides isolated nucleic acid molecules which encode novel fatty acid desaturase family members. The invention also provides recombinant expression vectors containing desaturase nucleic acid molecules, host cells into which the expression vectors have been introduced, and methods for large-scale production of long chain polyunsaturated fatty acids (LCPUFAs), e.g., DHA.Type: ApplicationFiled: December 29, 2011Publication date: April 19, 2012Applicant: Bioriginal Food & Science Corp.Inventors: Xiao Qiu, Haiping Hong
-
Patent number: 8158579Abstract: The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.Type: GrantFiled: November 30, 2010Date of Patent: April 17, 2012Assignee: BioRexis Pharmaceutical CorporationInventors: David James Ballance, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Patent number: 8158125Abstract: B-cell epitope peptides of HSP 65, particularly the peptides comprising the amino acid sequence substantially as denoted by SEQ ID: NOs. 1-5 and their biologically functional homologues and derivatives thereof. Also included are polyclonal and monoclonal antibodies directed against them and their compositions for passive immunization against inflammatory and autoimmune diseases and in the treatment of inflammatory and autoimmune diseases. Also encompassed are diagnostic uses of these antibodies, for identifying people at risk of developing arthritis or diabetes, and a method of monitoring progress of the disease conditions and disease prognosis.Type: GrantFiled: December 29, 2008Date of Patent: April 17, 2012Assignee: Hadasit Medical Research Services & Development Ltd.Inventors: Yaakov Naparstek, Rina Ulmansky, Yechezkei Kashi
-
Publication number: 20120088720Abstract: Disclosed herein are compounds that selectively inhibit members of the PTP family of enzymes. Synthesized compounds demonstrated selective inhibition of TC-PTP. Also provided are methods of using the compounds and formulations containing the compounds. Also described is a fluorescence-tagged combinatorial library synthesis and screening method. And methods of using these compounds to effect enzyme activity both in cells and in vitro as well as method of using these compounds to treat diseases in human and animals.Type: ApplicationFiled: April 8, 2010Publication date: April 12, 2012Applicant: Indiana University Research & Technology CorporatiInventors: Zhong-Yin Zhang, Sheng Zhang
-
Publication number: 20120088716Abstract: Method for increasing half-life of compounds in plasma and novel derivatives of such compounds.Type: ApplicationFiled: December 15, 2011Publication date: April 12, 2012Applicant: Novo Nordisk A/SInventors: Florencio Zaragoza Dörwald, Christine Bruun Schiødt, Thomas Kruse Hansen, Kjeld Madsen
-
Patent number: 8153583Abstract: Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists, and methods of making and using the foregoing are disclosed.Type: GrantFiled: November 30, 2005Date of Patent: April 10, 2012Inventors: Jill M. Carton, Shizhong Chen, Mark Cunningham, Anuk Das, Karen Duffy, Jill M. Giles-Komar, Theresa J. Goletz, David M. Knight, Roberta Lamb, Mouhamadou L. Mbow, Kristen Picha, Gopalan Raghunathan, Lani San Mateo, Robert T. Sarisky, Vedrana Stojanovic-Susulic, Nicole Stowell, Raymond Sweet, Shanrong Zhao
-
Publication number: 20120083442Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: ApplicationFiled: December 2, 2011Publication date: April 5, 2012Applicant: AMGEN INC.Inventors: HQ HAN, HOSUNG MIN, THOMAS CHARLES BOONE
-
Publication number: 20120077732Abstract: The present invention relates to cyclic peptides, comprising alternating D- and L- amino acids and wherein the peptide possesses immunomodulatory activity. The present invention also relates to pharmaceutical compositions comprising the cyclic peptides and to methods for the treatment of disease.Type: ApplicationFiled: November 24, 2009Publication date: March 29, 2012Applicant: SYDNEY WEST AREA HEALTH SERVICEInventors: Nicholas Manolios, Veronika Judit Bender, Marina Ali
-
Publication number: 20120076753Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.Type: ApplicationFiled: March 18, 2010Publication date: March 29, 2012Inventors: Ofer Mandelboim, Angel Porgador, Yaakov Naparstek, Chamutal Gur
-
Patent number: 8143217Abstract: The invention relates to a method to reduce the hypoglycemic events, especially sever hypoglycemic events resulting from insulin treatment, wherein the patient is treated with a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 18, 2006Date of Patent: March 27, 2012Assignee: Novartis AGInventors: Boerk Balkan, David G Holmes, Thomas E Hughes, Edwin B Villhauer
-
Publication number: 20120071399Abstract: Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner.Type: ApplicationFiled: June 28, 2011Publication date: March 22, 2012Applicant: ENZO BIOCHEM, INC.Inventors: JOSHUA RABBANI, JAMES J. DONEGAN, XIAOFENG LI
-
Publication number: 20120070449Abstract: A method of treating an inflammation in a subject in need thereof is disclosed. The method comprising administering to the subject an agent capable of down-regulating an activity or expression of CD151 in a lymphocyte, with the proviso that the agent is not CCL2, thereby treating the inflammation.Type: ApplicationFiled: May 27, 2010Publication date: March 22, 2012Applicant: Yeda Research And Development Co. Ltd.Inventors: Idit Shachar, Einat Toister
-
Publication number: 20120064127Abstract: It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises a) a lipid fraction comprising at least one of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b) a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c) a mineral fraction comprising at least one of manganese and molybdenum, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.Type: ApplicationFiled: November 11, 2011Publication date: March 15, 2012Applicant: N.V.NUTRICIAInventor: Robert J.J. Hageman
-
Publication number: 20120058119Abstract: The present invention relates to TR21 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR21 protein. TR21 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21 activity.Type: ApplicationFiled: November 14, 2011Publication date: March 8, 2012Applicant: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, David Hilbert
-
Publication number: 20120058938Abstract: The invention concerns the use of a nutritional composition for the treatment of disorders which are associated with malfunctioning in the uptake and use of food-derived energy in the human body. In particular, the invention concerns the use of a nutritional composition for the treatment of a disorder, which is mediated by a postprandial endocrine or neurological response in a human body, wherein the nutritional composition comprises one or more of a specific protein fraction, a specific carbohydrate fraction and a specific nutritional fiber fraction.Type: ApplicationFiled: March 9, 2010Publication date: March 8, 2012Applicant: N.V. NUTRICIAInventors: Robert Johan Joseph Hageman, Mirian Lansink
-
Publication number: 20120058105Abstract: The present invention provides methods for the prevention or treatment of one or more vascular complication(s) in a subject at risk of developing diabetes mellitus, impaired glucose tolerance and/or hyperglycemia or a subject suffering from diabetes mellitus, impaired glucose tolerance and/or hyperglycemia, wherein an amount of a composition effective to inhibit, repress, delay or otherwise reduce expression and/or activity and/or level of TXNIP and/or an amount of a composition effective to induce, enhance or otherwise increase expression and/or activity and/or level of TRX is/are administered to a subject in need thereof. The present invention also provides methods for identifying and isolating modulators of TXNIP expression and/or activity and/or level and/or TRX expression and/or activity and/or level for use in such therapeutic and prophylactic methods.Type: ApplicationFiled: June 26, 2009Publication date: March 8, 2012Inventors: Martin Kean Chong Ng, Louise Lorraine Dunn, Andrew Buckle
-
Patent number: 8129339Abstract: The invention relates to compositions and methods for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein a biologically active polypeptide, and a corticosteroid to modify the release profile and provide increased bioavailability.Type: GrantFiled: November 6, 2008Date of Patent: March 6, 2012Assignee: Alkermes Pharma Ireland LimitedInventors: Henry R. Costantino, Joyce M. Hotz, James R. Dasch, M. Gary I. Riley, Paul A. Burke, Susan A. Steitz-Abadi, Stephen E. Zale
-
Publication number: 20120053119Abstract: The present invention provides various methods for increasing beta cell mass. In certain embodiments, such methods include steps of administering to a subject an effective amount of: (a) SDF1, a polypeptide having amino acid sequence substantially homologous thereto, or a fragment thereof capable of increasing beta cell survival; and (b) GLP-1 Exendin-4, a polypeptide having amino acid sequence substantially homologous to GLP-1 or Exendin-4, or a fragment of GLP-1 or Exendin-4 capable of promoting beta cell proliferation, whereby beta cell mass is increased in the subject.Type: ApplicationFiled: February 11, 2010Publication date: March 1, 2012Inventors: Joel F. Habener, Zhengyu Liu, Tatsuya Yano
-
Publication number: 20120052130Abstract: Compounds of Formula (I) that modulate the activity of the G-protein-coupled receptor GPFM 19 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.Type: ApplicationFiled: April 12, 2010Publication date: March 1, 2012Inventors: Etzer Darout, Michael Paul DeNinno, Kentaro Futatsugi, Cristiano Ruch Werneck Guimaraes, Bruce Allen Lefker, Vincent Mascitti, Kim Francis McClure, Michael John Munchhof, Ralph Pelton Robinson, JR.
-
Publication number: 20120052069Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.Type: ApplicationFiled: May 4, 2010Publication date: March 1, 2012Applicant: AMGEN INCInventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
-
Publication number: 20120053113Abstract: The present invention provides compositions and pharmaceutical formulations of IaIp derived from plasma. Also provided are methods for the manufacture of the IaIp compositions and formulations, as well as method for the treatment of diseases associated with IaIp dysfunction.Type: ApplicationFiled: July 22, 2011Publication date: March 1, 2012Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Shawn F. Bairstow, Jennifer Hutsell, Sindhu Ramachandran
-
Publication number: 20120046224Abstract: Enterally administered calcitonin family members other than amylin, particularly calcitonin itself, are effective to treat Type I diabetes, Type II diabetes or metabolic syndrome, for mitigating insulin resistance, and for reducing serum glucose levels.Type: ApplicationFiled: March 10, 2010Publication date: February 23, 2012Applicant: NORDIC BIOSCIENCE A/SInventors: Morten A. Karsdal, Claus Christiansen
-
Publication number: 20120046221Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: April 1, 2011Publication date: February 23, 2012Inventors: Craig A. Rosen, William A. Haseltine, David J. Ballance, Andrew J. Tuner, Steven M. Ruben
-
Publication number: 20120046219Abstract: The invention relates to melanocortin receptor-specific cyclic peptides of Formula (I) or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4a, R4b, R4c, R5, x and y are as defined in the specification. These compounds are particularly useful in the treatments of energy homeostasis and metabolism related (e.g. diabetes), food intake related and/or energy balance and body weight related diseases, disorders and/or conditions, including obesity, overweight and diseases, disorders and/or conditions associated with obesity and/or overweight, such as type 2 diabetes and metabolic syndrome.Type: ApplicationFiled: October 26, 2011Publication date: February 23, 2012Applicant: AstraZeneca ABInventors: John H. DODD, Yi-Qun Shi, Wei Yang
-
Publication number: 20120046222Abstract: The disclosure provides N-terminus conformationally constrained compounds, which may comprise peptide mimetics and/or amino acid substitutions, which may be used in peptides, such as GLP-1 receptor agonist compounds, to induce a ?-turn secondary structure at the N-terminus. The N-terminus conformationally constrained compounds may be used for research purposes; to produce GLP-1 receptor agonist compounds having improved GLP-1 receptor binding activity, enzymatic stability, or in vivo glucose lowering activity; and to develop GLP-1 receptor agonist compounds which have fewer amino acid residues. The disclosure also provides GLP-1 receptor agonist compounds, such as exendins, exendin analogs, GLP-1 (7-37), GLP-1 (7-37) analogs, comprising the N-terminus conformationally constrained compounds. The compounds are useful for treating various diseases, such as diabetes and obesity. The disclosure also provides methods for chemically synthesizing the N-terminus conformationally constrained compounds.Type: ApplicationFiled: March 26, 2010Publication date: February 23, 2012Applicant: Amylin Pharmaceuticals, Inc.Inventors: Josue Alfaro-Lopez, Abhinandini Sharma, Soumitra S. Ghosh
-
Publication number: 20120046217Abstract: The present invention relates to: TNF-? antagonists containing IGFBP5 protein, variants thereof, or fragments thereof; and the use of the TNF-? antagonists. More specifically, the present invention relates to: a polynucleotide encoding the protein, variants thereof, or fragments thereof; a vector containing the polynucleotide; a transformant containing the vector; and a method for screening a therapeutic agent for TNF-? overexpression-related diseases by checking whether the mutual reaction thereof is facilitated after treating with candidates to the cell expressing the IGFBP5 protein, variants thereof, or fragments thereof, and the TNER1.Type: ApplicationFiled: June 30, 2009Publication date: February 23, 2012Applicant: SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATIONInventors: Je-Ho Lee, Jae-Ryoung Hwang, Jae-Ho Huh
-
Patent number: 8119593Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.Type: GrantFiled: August 11, 2009Date of Patent: February 21, 2012Assignee: MannKind CorporationInventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
-
Patent number: 8119591Abstract: Methods and compositions are described to regenerate cartilage in a partial thickness defect or area of reduced volume of articular cartilage comprising an infiltration suppressor agent and a columnar growth promoting agent.Type: GrantFiled: August 1, 2006Date of Patent: February 21, 2012Assignee: Genera Istrazivanja d.o.o.Inventors: Slobodan Vukicevic, Mislav Jelic
-
Patent number: 8114837Abstract: The invention relates to a GLP-1 secretagogue and an inhibitor of postprandial rise in blood glucose, containing ?-casein as an active ingredient, and a food or drink for promoting GLP-1 secretion and an inhibitory food or drink of postprandial rise in blood glucose, containing a milk-derived casein protein wherein ?-casein accounts for 60% by mass or more of the milk-derived casein.Type: GrantFiled: February 12, 2010Date of Patent: February 14, 2012Assignee: Morinaga Milk Industry Co., Ltd.Inventors: Yousuke Itoh, Kouji Nomaguchi, Muneo Yamada
-
Publication number: 20120035099Abstract: Derivatives of Fibroblast Growth Factor 21 which have improved properties for treating diabetes can be prepared by a recombinant process.Type: ApplicationFiled: June 6, 2011Publication date: February 9, 2012Applicant: NOVO NORDISK A/SInventors: WILLIAM PATRICK GARIBAY, HELLE WÖLDIKE, XUJIA ZHANG, HENNING THØGERSEN, PETER KRESTEN NIELSEN, BIRGITTE ANDERSEN, JISHU WANG, KRISTIAN SASS BAK-JENSEN, TINA MØLLER TAGMOSE
-
Publication number: 20120027720Abstract: The present invention provides novel peptide conjugates. Peptide conjugates of the invention can be used as therapeutic agents. Peptide conjugates invention may also be used to deliver one or more additional active agents. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide conjugate of the invention, optionally.Type: ApplicationFiled: June 24, 2011Publication date: February 2, 2012Inventors: Amir TAMIZ, Sefik Alkan
-
Publication number: 20120028892Abstract: The invention is directed to a compound according to formula (I). The compounds of formula (I) include prodrugs, pharmaceutically acceptable salts, stereoisomer mixtures, and enantiomers thereof. The invention is also directed to a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier and to methods for treating diabetes by administering such a pharmaceutical composition alone or in combination with other therapeutic agents. The invention is also directed to inhibitors of fructose-1,6-bisphosphatase.Type: ApplicationFiled: February 4, 2010Publication date: February 2, 2012Applicant: Trustees of Boston CollegeInventors: Evan R. Kantrowitz, Sabrina Heng
-
Publication number: 20120030779Abstract: Disclosed herein is a non-human animal model of protein aggregation cardiomyopathy. Also disclosed are compo-sitions and methods of treating or preventing a condition in a subject caused or exacerbated by reductive stress. Also disclosed are compositions and methods of predicting, detecting, or monitoring reductive stress in a subject.Type: ApplicationFiled: January 18, 2008Publication date: February 2, 2012Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDTIONInventors: Ivor J. Benjamin, Namakkal S. Rajasekaran, Thomas P. Kennedy
-
Publication number: 20120028894Abstract: Use of an isolated peptide comprising an amino acid sequence being no more than 25 amino acids in length, the amino acid sequence comprising at least one aspartate or a homolog thereof, the peptide having an Insulin-Degrading Enzyme (IDE) inhibitory activity, for the manufacture of a medicament identified for treating a disease selected from the group consisting of diabetes, obesity, hyperglycemia, retinal damage, renal failure, nerve damage, microvascular damage and varicella-zoster virus (VZV) infection is disclosed.Type: ApplicationFiled: February 2, 2010Publication date: February 2, 2012Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Dan Frenkel, Adi Kopelevich, Veronica Lifshitz, Tali Benromano, Nofit Borenstein
-
Publication number: 20120028893Abstract: Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis. Ad-36 E4 orf 1 protein can be used to increase insulin sensitivity and ameliorate diabetes. Additionally, drugs that mimic the action of Ad-36 E4 orf 1 protein could be found. Ad-36 E4 orf 1 could also be used to increase fat cells in lipodystrophy. We have also discovered that Ad-36 infection in human skeletal muscle cells increased differentiation and insulin independent glucose uptake. It is expected that infection with Ad-36 E4 orf 1 gene will also cause these effects.Type: ApplicationFiled: July 7, 2011Publication date: February 2, 2012Applicants: Wayne State University, Board of Supervisors of Louisiana State University & Agricultural & Mechanical CollegeInventors: Nikhil V. Dhurandhar, Thomas C. Holland, Zhong Q. Wang
-
Publication number: 20120028888Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the intracellular loops and domains of the the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as heart diseases (e.g., hypertension and tension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.Type: ApplicationFiled: November 4, 2009Publication date: February 2, 2012Inventors: Jay Janz, Athan Kuliopulos, Thomas J. McMurry
-
Publication number: 20120028880Abstract: The present invention concerns the fields of molecular medicine and targeted delivery of therapeutic agents. More specifically, the present invention relates to the identification of novel peptide sequences that incorporate the amino acids Leu-Pro-Arg (LPR), and particularly D(LPR), that selectively target VEGFR-I and NRP-I expressing cells. Targeted molecules in accor-dance with the invention are useful in the treatment and detection of neovascular or angiogenic VEGF associated disorders, including but not limited to cancer, obesity, diabetes, asthma, arthritis, cirrhosis and ocular diseases.Type: ApplicationFiled: August 8, 2008Publication date: February 2, 2012Inventors: Renata Pasqualini, Wadih Arap, Ricardo Giordano, Marina Cardó-Vila, Ana Paula Valente, Fabio Ceneviva Lacerda De Almeida
-
Publication number: 20120028895Abstract: Described are methods of improving glycemic control/improving insulin sensitivity by administering an inhibitor of serum response factor (SRF) activity, and methods of identifying new compounds for use in the described methods of treatment.Type: ApplicationFiled: July 11, 2011Publication date: February 2, 2012Applicant: Joslin Diabetes Center, Inc.Inventors: Mary Elizabeth Patti, Wanzhu Jin, Allison B. Goldfine
-
Publication number: 20120021973Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.Type: ApplicationFiled: November 24, 2009Publication date: January 26, 2012Applicant: Novo Nordisk A/SInventors: Jesper F. Lau, Ulrich Sensfuss, Kilian Waldemar Conde-Frieboes, Birgitte Schjellerup Wulff
-
Publication number: 20120021971Abstract: The invention relates to a heat shock protein from alfalfa and/or a hydrolysate of a heat shock protein from alfalfa in the manufacture of a food product for the prophylactic or therapeutic treatment of a chronic inflammatory disorder. Further, the invention relates to a clinical food product comprising heat shock protein from alfalfa and/or a hydrolysate of a heat shock protein from alfalfa.Type: ApplicationFiled: July 29, 2011Publication date: January 26, 2012Applicant: Alfa Biogene International B.V.Inventor: Julia Lax
-
Publication number: 20120021979Abstract: The present invention involves the use of GLP-1 and its analogs or GLP-1 receptor agonists to modulate dopamine transporter signaling. The implications of this ability include the use of MT-1 and its analogs or GLP-1 receptor agonists, such as exendin-4, to blunt behavioral response to addictive drugs, to decrease drug dependence, to prevent drug abuse relapse, and to treat brain disorders such as neuropsychiatric disorders including ADHD. The present invention also involves the use of GLP-1 and its analogs or GLP-1 receptor agonists to activate GLP-1R in penile tissue, such as for the treatment of erectile dysfunction either as a monotherapy or in combinations with other treatments, such as PDE 5 inhibitors.Type: ApplicationFiled: June 10, 2011Publication date: January 26, 2012Inventors: Aurelio Galli, Kevin Erreger, Kevin Niswender, Sabrina Robertson, Christine Saunders, Heinrich J.G. Matthies, Adeola Davis
-
Publication number: 20120021972Abstract: The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-I receptor agonistic activity.Type: ApplicationFiled: December 10, 2008Publication date: January 26, 2012Inventors: Rajesh H. Bahekar, Mukul R. Jain, Pankaj Ramanbhai Patel
-
Publication number: 20120015868Abstract: The present invention provides a metastin derivative in which the amino acids comprising metastin were modified by alternative chemical substituents resulting in metastin derivitives, having excellent blood stability and exhibiting cancer metastasis inhibiting action or cancer growth inhibiting action.Type: ApplicationFiled: June 29, 2011Publication date: January 19, 2012Applicant: Takeda Pharmaceutical Company LimitedInventors: Chieko Kitada, Taiji Asami, Naoko Nishizawa, Tetsuya Ohtaki, Naoki Tarui, Hirokazu Matsumoto, Jiro Noguchi, Hisanori Matsui
-
Publication number: 20120015876Abstract: The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a GLP-1 agonist (e.g., exendin-4 or an exendin-4 analog). The compounds of the invention can be used to treat any disease where increased GLP-1 activity is desired, for example, metabolic diseases, such as obesity and diabetes.Type: ApplicationFiled: October 15, 2009Publication date: January 19, 2012Applicant: Angiochem Inc.Inventors: Jean-Paul Castaigne, Michel Demeule, Catherine Gagnon, Betty Lawrence
-
Patent number: 8097586Abstract: Novel exendins with modifications at one or more of following positions: 2, 14, 27 or 28 and polyethylene glycol derivatives thereof are provided. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.Type: GrantFiled: January 10, 2006Date of Patent: January 17, 2012Assignee: Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.Inventors: Aifeng Lv, Changan Sun, Yali Wang
-
Publication number: 20120010136Abstract: The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. The invention relates to peptides corresponding to fragments of CD31 that inhibit T-cell response, and to their use in the treatment of thrombotic disorders such as atherothrombosis and autoimmune disorders.Type: ApplicationFiled: June 30, 2009Publication date: January 12, 2012Inventors: Giuseppina Caligiuri, Antonino Nicoletti